Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute
Xylyx Bio, Inc., a biotechnology company developing groundbreaking solutions for drug discovery and tissue modeling and repair, announced today that it has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF). Read more >>